Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with non-squamous non-small cell lung cancer (a specific type of lung cancer) that can be removed by surgery
- People aged between 18 and 65 years old
- People of any gender (male or female)
- People who are generally well enough to carry out normal daily activities, with little or no physical limitations (confirm with trial site)
- People who have not previously received any treatment for their lung cancer, including surgery, chemotherapy, radiation therapy, or biological treatments
- People whose lungs are healthy enough to withstand the planned lung surgery
Who may not be able to join:
- People diagnosed with small cell lung cancer or squamous cell non-small cell lung cancer (different types of lung cancer)
- People who have previously received certain immune system treatments, including anti-PD1, anti-PDL1, or anti-CTLA4 therapies
- People who have previously used medications that target blood vessel growth (anti-angiogenic drugs)
- People who have a known allergy to any ingredient in the study drug or the chemotherapy drugs used in the trial
- People who have any serious or uncontrolled medical conditions
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jianxing He, The First Affiliated Hospital of Guangzhou Medical University
Phone: +86-20-83062807
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Pathological complete response
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.